Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Indiana University
How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
Answer from: Medical Oncologist at Community Practice
Tem/cape -- responses are good for pancreatic NET. PRRT Is great but so expensive. I’m finding it so hard to get.
Sign in or Register to read more
6227
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
How would you approach dose modifications and/or frequency of lenalidomide in patients with advanced renal impairment (eGFR <30)?
Would you consider circulating DNA assay in resected node-negative deficient MMR colon cancer off-trial to guide your treatment?
What is your approach for adjuvant chemotherapy for a patient with colon adenocarcinoma, pMMR, T2 with 3 positive lymph nodes and 2 pericolic adipose tumor deposits?
How would you treat newly diagnosed stage IV GEJ adenocarcinoma with both Claudin 18.2 and HER2 (3+ via IHC) overexpression?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
In a patient with prior RT to the prostate and SVs and newly diagnosed, locally advanced rectal cancer at 10-15 cm, would you offer preoperative chemoradiation?
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?